Aquinox scraps bladder pain drug after Phase 3 failure

Canadian Aquinox Pharmaceuticals' once-daily, oral rosiptor (AQX-1125) failed to meet the primary endpoint of the Phase 3 LEADERSHIP 301 trial in interstitial cystitis/bladder pain syndrome (IC/BPS), leaving the company's stock value in tatters.